loading
Precedente Chiudi:
$30.17
Aprire:
$29.5
Volume 24 ore:
200.73K
Relative Volume:
0.28
Capitalizzazione di mercato:
$1.91B
Reddito:
$87.56M
Utile/perdita netta:
$-167.47M
Rapporto P/E:
-12.52
EPS:
-2.34
Flusso di cassa netto:
$-148.20M
1 W Prestazione:
-3.14%
1M Prestazione:
-4.56%
6M Prestazione:
-34.86%
1 anno Prestazione:
-14.43%
Intervallo 1D:
Value
$29.15
$29.79
Intervallo di 1 settimana:
Value
$29.15
$31.47
Portata 52W:
Value
$19.45
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
Nome
Kymera Therapeutics Inc
Name
Telefono
857-285-5314
Name
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
Dipendente
208
Name
Cinguettio
Name
Prossima data di guadagno
2025-02-21
Name
Ultimi documenti SEC
Name
KYMR's Discussions on Twitter

Confronta KYMR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
KYMR
Kymera Therapeutics Inc
29.30 1.95B 87.56M -167.47M -148.20M -2.34
Biotechnology icon
ONC
Beigene Ltd Adr
240.75 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.21 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.97 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.17 5.92B 0 -153.72M -103.81M -2.00

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-13 Iniziato Citigroup Buy
2024-12-10 Iniziato BTIG Research Buy
2024-12-06 Iniziato BMO Capital Markets Market Perform
2024-12-02 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-11-18 Iniziato Stephens Overweight
2024-09-09 Ripresa Leerink Partners Outperform
2024-08-26 Aggiornamento Wolfe Research Peer Perform → Outperform
2024-04-22 Iniziato Oppenheimer Outperform
2024-02-15 Iniziato Wolfe Research Peer Perform
2024-01-04 Aggiornamento JP Morgan Neutral → Overweight
2024-01-03 Downgrade BofA Securities Buy → Neutral
2023-12-19 Downgrade Wells Fargo Overweight → Equal Weight
2023-06-30 Iniziato Truist Buy
2023-05-05 Aggiornamento Raymond James Mkt Perform → Outperform
2022-12-06 Downgrade Credit Suisse Outperform → Neutral
2022-11-08 Iniziato Raymond James Mkt Perform
2022-08-15 Iniziato Jefferies Buy
2022-08-03 Iniziato Goldman Buy
2022-07-20 Iniziato SVB Leerink Mkt Perform
2022-04-28 Iniziato Credit Suisse Outperform
2022-03-10 Iniziato JP Morgan Neutral
2022-02-10 Iniziato Wells Fargo Overweight
2021-09-30 Iniziato B. Riley Securities Neutral
2021-09-30 Iniziato Stifel Buy
2021-09-10 Downgrade BofA Securities Buy → Neutral
2021-05-21 Iniziato UBS Buy
2021-04-14 Iniziato Berenberg Buy
2020-12-04 Iniziato H.C. Wainwright Buy
2020-09-15 Iniziato BofA Securities Neutral
2020-09-15 Iniziato Cowen Outperform
2020-09-15 Iniziato Guggenheim Buy
2020-09-15 Iniziato Morgan Stanley Equal-Weight
Mostra tutto

Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie

pulisher
May 20, 2025

Kymera Therapeutics (KYMR) Receives 'Buy' Rating from Stifel with $55 Price Target | KYMR Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Kymera Therapeutics (KYMR) Gains Buy Rating from Stifel with Promising Outlook | KYMR Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Kymera Therapeutics (KYMR) Showcases Promising Preclinical Data for Asthma Treatment | KYMR Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study - Investing.com

May 19, 2025
pulisher
May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study By Investing.com - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics presents preclinical data for KT-621 - TipRanks

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference | KYMR Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Breakthrough: New Oral Asthma Drug Shows Superior Results to Dupilumab in Latest Clinical Data - Stock Titan

May 19, 2025
pulisher
May 14, 2025

Transcript : Kymera Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights - Investing.com

May 14, 2025
pulisher
May 14, 2025

Kymera TherapeuticsIntriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha

May 14, 2025
pulisher
May 13, 2025

Kymera Therapeutics (KYMR) Target Price Adjusted by UBS | KYMR S - GuruFocus

May 13, 2025
pulisher
May 13, 2025

UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Kymera Therapeutics (KYMR) Target Price Revised by UBS | KYMR St - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week - simplywall.st

May 13, 2025
pulisher
May 13, 2025

When the Price of (KYMR) Talks, People Listen - news.stocktradersdaily.com

May 13, 2025
pulisher
May 12, 2025

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts - Benzinga

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Str - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK

May 12, 2025
pulisher
May 12, 2025

Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech

May 12, 2025
pulisher
May 12, 2025

B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks

May 12, 2025
pulisher
May 10, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Kymera advances oral drug for autoimmune diseases - Investing.com

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Strong Earnings - Defense World

May 10, 2025
pulisher
May 10, 2025

Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Kymera advances oral drug for autoimmune diseases By Investing.com - Investing.com India

May 10, 2025
pulisher
May 10, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 - Investing.com

May 10, 2025
pulisher
May 09, 2025

Kymera (KYMR) Financial Update: Strong Cash Position Supports Future Developments | KYMR Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Reports Strong Pipeline Progress - TipRanks

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Launches Innovative Oral Immunology P - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars t - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Stro - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics’ Earnings Call: Resilience and Strategic Growth - TipRanks

May 09, 2025
pulisher
May 09, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 By Investing.com - Investing.com South Africa

May 09, 2025
pulisher
May 09, 2025

Truist maintains Buy on Kymera stock, reiterates $53 target By Investing.com - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 09, 2025
pulisher
May 09, 2025

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging - Zacks Investment Research

May 09, 2025
pulisher
May 09, 2025

Kymera (KYMR) Financial Update: Strong Cash Position Supports Fu - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars to $22.1M, Beating Estimates; Net Loss Widens - GuruFocus

May 09, 2025

Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.16
price down icon 17.27%
$31.18
price down icon 3.94%
$578.71
price down icon 0.54%
$286.89
price down icon 0.52%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
Capitalizzazione:     |  Volume (24 ore):